TRATON SE

  • WKN: TRAT0N
  • ISIN: DE000TRAT0N7
  • Land: Deutschland

Nachricht vom 29.09.2021 | 19:41

TRATON SE: Chairman leaves the Executive Board of TRATON SE

TRATON SE / Key word(s): Personnel
TRATON SE: Chairman leaves the Executive Board of TRATON SE

29-Sep-2021 / 19:41 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Chairman leaves the Executive Board of TRATON SE

Munich, 29 September 2021 - The Supervisory Board of TRATON SE and Mr. Matthias Gründler have agreed today that Mr. Gründler will leave the Executive Board of TRATON SE by mutual consent with effect as of 30 September 2021. Mr. Gründler will be succeeded by Mr. Christian Levin as Chairman of the Executive Board of TRATON SE. In addition, Mr. Christian Schulz will leave the Executive Board of TRATON SE by mutual consent with effect as of 30 September 2021. Mr. Schulz will be succeeded by Mrs. Annette Danielski on the Executive Board of TRATON SE.

Contact:

Name: Dr. Klaus Schartel
Position: General Counsel
Tel.: +49 152 04265185
E-Mail: klaus.schartel@traton.com


29-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

IGEA Pharma N.V.

Original-Research: IGEA Pharma N.V. (von GBC AG): Kaufen

29. November 2021